Thromboprophylaxis rates in US medical centers: success or failure?
about
A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical recordsCancer and Venous Thromboembolic Disease: A Review.Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study.The potential benefits of low-molecular-weight heparins in cancer patientsAre hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics CommitteesPhysician alerts to prevent symptomatic venous thromboembolism in hospitalized patientsComputerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyondPerioperative pharmacologic prophylaxis for venous thromboembolism in colorectal surgeryRate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United StatesEconomic burden of venous thromboembolism in hospitalized patients.Thromboprophylaxis use in medical and surgical inpatients and the impact of an electronic risk assessment tool as part of a multi-factorial intervention. A report on behalf of the elVis study investigatorsVenous thromboembolism in patients with diabetes mellitus.Cancer-associated thrombosis: prevention and treatmentStrategies to enhance venous thromboprophylaxis in hospitalized medical patients (SENTRY): a pilot cluster randomized trial.Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.Venous thromboembolism in hospitalised patients: a public health crisis?Cancer, clots and consensus: new understanding of an old problem.Preventing venous thromboembolism in cancer patients: can we do better?Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis?Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient.The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies.The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients.Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.Venous thromboembolism in COPD hospitalized patients.Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients.Rural relevant quality measures for critical access hospitals.Appropriate VTE prophylaxis is associated with lower direct medical costs.Deep vein thrombosis (DVT) and pulmonary embolism (PE): awareness and prophylaxis practices reported by patients with cancer.Prevention and treatment of venous thromboembolism in patients with cancer.Venous thromboembolism prophylaxis in the United States: still room for improvement.Prevalence of stroke/transient ischemic attack among patients with acute coronary syndromes in a real-world setting.Lack of thromboprophylaxis across the care continuum in US medical patients.Improving venous thromboembolism risk assessment compliance using the electronic tool in admitted medical patients.Impact of the ENDORSE study results on thromboprophylaxis prescribing patterns in medical patients attending the emergency department.A simple reminder system improves venous thromboembolism prophylaxis rates and reduces thrombotic events for hospitalized patients1.Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis.Adherence to guideline-directed venous thromboembolism prophylaxis among medical and surgical inpatients at 33 academic medical centers in the United States.
P2860
Q30886141-B1759C14-2A12-4FDF-9095-12471A951FDFQ33439089-0A9DD512-0E75-40D9-B7EE-3A87ACD47724Q33691499-D2EEA631-88E4-4609-AB82-5E22CBFA2189Q33698360-6D06ADC5-0866-477C-B221-D9B4658FDE04Q33722129-C964D84A-14A7-4BE7-A5DD-69651448E51AQ33763866-B6991952-6591-47BC-A340-E46AE2A40DFBQ33765274-D0903ABF-8F0E-4D6D-BD9A-70DDEBC7388BQ33982604-C8174104-4443-4339-BDD2-84A4950C9BBCQ33988196-0D68FC38-4140-43E3-9072-277A4F271B18Q34211162-D85A580C-0F53-4A9E-ACCE-A91E0408EF21Q34580375-C8502622-4CA3-43D0-8838-9FB2325A3A0CQ34994523-5D450499-13B0-489D-A7F4-589ACEC52775Q35206794-E28D45DA-CDE0-47FD-9E7A-50E4CCA6357BQ36178744-6F3435E9-6122-4A17-91B7-12136B4FCA62Q36410631-36F47D9F-556A-4EE4-A146-31473B9D2BF4Q36541962-A34A8058-27BD-463A-BF07-FEDFF9EC3DA1Q37023306-A1EE9748-A897-462E-AF2D-E15BC4563D73Q37137952-15EF41CF-9DD3-412B-A6F9-65F6A9BE597CQ37393386-39F13310-C018-405B-B9E5-50FE73E52DA3Q37481823-6AED465B-8991-439A-9ED6-4CE5E5602569Q37481830-517A8D88-C4FA-4C48-8B7B-52615744E784Q37516892-2223D2A2-ED3D-499F-B3F5-D381EAD9E012Q37752250-14493303-1DE6-4E62-9593-6DA0F78236A8Q37777972-FA92E2B7-4E44-4CE5-99D6-83ED8F285D32Q37789425-095906A1-FE83-4CD9-93EA-20880C83E1FEQ37889269-A799CDB8-B077-4E3B-8D68-D2DFF7C60325Q37948005-2B32FFAE-F06B-4270-91E1-EF7C799F1482Q38079539-1F131268-5D82-4E5F-85BC-69F5E4596B50Q39440943-D2815325-BF87-411F-8CA7-D7CCB089550FQ39958476-22C6E5E9-0BCB-468F-B517-138249EE85DDQ41581103-0D178A71-C703-46E9-A1E4-7B256C0689BAQ41877145-8A1F9AB1-C064-48B1-8735-4B837163E7B7Q42783150-96B3BED2-1D3C-4189-A419-F000C90ACE51Q42822409-6941B754-2D98-4157-82AA-A48D7255924BQ43055026-3829BBA6-56E7-4E81-9B21-33E8CA8F9745Q43114444-AEF16CA7-D4CD-479F-B6FC-33FB4E9785E9Q43598901-960AE1DB-E766-4698-829F-691AC4BDCE7DQ44575292-1AB4F3CD-7709-4915-8472-39B0BF7CA5F3Q45187455-86C73AC1-46E3-405E-BA67-E597D778F6B0Q45765797-A4E62C18-AEAD-456A-9CC3-B86A908A3E63
P2860
Thromboprophylaxis rates in US medical centers: success or failure?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Thromboprophylaxis rates in US medical centers: success or failure?
@en
Thromboprophylaxis rates in US medical centers: success or failure?
@nl
type
label
Thromboprophylaxis rates in US medical centers: success or failure?
@en
Thromboprophylaxis rates in US medical centers: success or failure?
@nl
prefLabel
Thromboprophylaxis rates in US medical centers: success or failure?
@en
Thromboprophylaxis rates in US medical centers: success or failure?
@nl
P2093
P2860
P1476
Thromboprophylaxis rates in US medical centers: success or failure?
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2007.02650.X
P577
2007-08-01T00:00:00Z